Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 43 entries
Sorted by: Best Match Show Resources per page
The durability of oral diabetic medications: Time to A1c baseline and a review of common oral medications used by the primary care provider.

Endocrinology, diabetes and metabolism journal

Cherukuri L, Smith MS, Tayek JA.
PMID: 30370022
Endocrinol Diabetes Metab J. 2018 Sep;2(3). Epub 2018 Jul 08.

INTRODUCTION: Cost of generic medications has risen more in the past few years than any other time in history. While medical insurance covers much of these costs, health care professionals can better provide medications that have the longest duration...

Cite
Cherukuri L, Smith MS, Tayek JA. The durability of oral diabetic medications: Time to A1c baseline and a review of common oral medications used by the primary care provider. Endocrinol Diabetes Metab J. 2018;2(3)
Cherukuri, L., Smith, M. S., & Tayek, J. A. (2018). The durability of oral diabetic medications: Time to A1c baseline and a review of common oral medications used by the primary care provider. Endocrinology, diabetes and metabolism journal, 2(3), .
Cherukuri, Lavanya, et al. "The durability of oral diabetic medications: Time to A1c baseline and a review of common oral medications used by the primary care provider." Endocrinology, diabetes and metabolism journal vol. 2,3 (2018).
Cherukuri L, Smith MS, Tayek JA. The durability of oral diabetic medications: Time to A1c baseline and a review of common oral medications used by the primary care provider. Endocrinol Diabetes Metab J. 2018 Sep;2(3). Epub 2018 Jul 08. PMID: 30370022; PMCID: PMC6200420.
Copy Download .nbib Format: NLM
Gene Set Enrichment Analsyes Identify Pathways Involved in Genetic Risk for Diabetic Retinopathy.

American journal of ophthalmology

Sobrin L, Susarla G, Stanwyck L, Rouhana JM, Li A, Pollack S, Igo RP, Jensen RA, Li X, Ng MCY, Smith AV, Kuo JZ, Taylor KD, Freedman BI, Bowden DW, Penman A, Chen CJ, Craig JE, Adler SG, Chew EY, Cotch MF, Yaspan B, Mitchell P, Wang JJ, Klein BEK, Wong TY, Rotter JI, Burdon KP, Iyengar SK, Segrè AV.
PMID: 34166655
Am J Ophthalmol. 2022 Jan;233:111-123. doi: 10.1016/j.ajo.2021.06.014. Epub 2021 Jun 21.

To identify functionally related genes associated with diabetic retinopathy (DR) risk using gene set enrichment analyses applied to genome-wide association study meta-analyses.METHODS: We analyzed DR GWAS meta-analyses performed on 3246 Europeans and 2611 African Americans with type 2 diabetes....

Cite
Sobrin L, Susarla G, Stanwyck L, et al. Gene Set Enrichment Analsyes Identify Pathways Involved in Genetic Risk for Diabetic Retinopathy. Am J Ophthalmol. 2021;233:111-123doi: 10.1016/j.ajo.2021.06.014.
Sobrin, L., Susarla, G., Stanwyck, L., Rouhana, J. M., Li, A., Pollack, S., Igo, R. P., Jensen, R. A., Li, X., Ng, M. C. Y., Smith, A. V., Kuo, J. Z., Taylor, K. D., Freedman, B. I., Bowden, D. W., Penman, A., Chen, C. J., Craig, J. E., Adler, S. G., Chew, E. Y., Cotch, M. F., Yaspan, B., Mitchell, P., Wang, J. J., Klein, B. E. K., Wong, T. Y., Rotter, J. I., Burdon, K. P., Iyengar, S. K., & Segrè, A. V. (2022). Gene Set Enrichment Analsyes Identify Pathways Involved in Genetic Risk for Diabetic Retinopathy. American journal of ophthalmology, 233111-123. https://doi.org/10.1016/j.ajo.2021.06.014
Sobrin, Lucia, et al. "Gene Set Enrichment Analsyes Identify Pathways Involved in Genetic Risk for Diabetic Retinopathy." American journal of ophthalmology vol. 233 (2022): 111-123. doi: https://doi.org/10.1016/j.ajo.2021.06.014
Sobrin L, Susarla G, Stanwyck L, Rouhana JM, Li A, Pollack S, Igo RP, Jensen RA, Li X, Ng MCY, Smith AV, Kuo JZ, Taylor KD, Freedman BI, Bowden DW, Penman A, Chen CJ, Craig JE, Adler SG, Chew EY, Cotch MF, Yaspan B, Mitchell P, Wang JJ, Klein BEK, Wong TY, Rotter JI, Burdon KP, Iyengar SK, Segrè AV. Gene Set Enrichment Analsyes Identify Pathways Involved in Genetic Risk for Diabetic Retinopathy. Am J Ophthalmol. 2022 Jan;233:111-123. doi: 10.1016/j.ajo.2021.06.014. Epub 2021 Jun 21. PMID: 34166655; PMCID: PMC8678352.
Copy Download .nbib Format: NLM
Calcium Supplements and Cardiovascular Disease: A Review.

American journal of lifestyle medicine

Waldman T, Sarbaziha R, Merz CN, Shufelt C.
PMID: 26345134
Am J Lifestyle Med. 2015 Jul 01;9(4):298-307. doi: 10.1177/1559827613512593.

Dietary or supplemental calcium intake has long been encouraged for optimal bone health. However, more recently, the safety of calcium supplementation has been questioned because of a possible association between supplemental calcium and cardiovascular risk. Whereas calcium may have...

Cite
Waldman T, Sarbaziha R, Merz CN, et al. Calcium Supplements and Cardiovascular Disease: A Review. Am J Lifestyle Med. 2015;9(4):298-307doi: 10.1177/1559827613512593.
Waldman, T., Sarbaziha, R., Merz, C. N., & Shufelt, C. (2015). Calcium Supplements and Cardiovascular Disease: A Review. American journal of lifestyle medicine, 9(4), 298-307. https://doi.org/10.1177/1559827613512593
Waldman, Talya, et al. "Calcium Supplements and Cardiovascular Disease: A Review." American journal of lifestyle medicine vol. 9,4 (2015): 298-307. doi: https://doi.org/10.1177/1559827613512593
Waldman T, Sarbaziha R, Merz CN, Shufelt C. Calcium Supplements and Cardiovascular Disease: A Review. Am J Lifestyle Med. 2015 Jul 01;9(4):298-307. doi: 10.1177/1559827613512593. PMID: 26345134; PMCID: PMC4560115.
Copy Download .nbib Format: NLM
Cardiac magnetic resonance imaging for myocardial perfusion and diastolic function-reference control values for women.

Cardiovascular diagnosis and therapy

Bakir M, Wei J, Nelson MD, Mehta PK, Haftbaradaran A, Jones E, Gill E, Sharif B, Slomka PJ, Li D, Shufelt CL, Minissian M, Berman DS, Bairey Merz CN, Thomson LE.
PMID: 26885495
Cardiovasc Diagn Ther. 2016 Feb;6(1):78-86. doi: 10.3978/j.issn.2223-3652.2015.09.03.

Angina, heart failure with preserved ejection fraction (HFpEF) and coronary microvascular dysfunction (CMD) in the absence of obstructive coronary artery disease (CAD) are more common in women and are associated with adverse cardiovascular prognosis. Cardiac magnetic resonance imaging (CMRI)...

Cite
Bakir M, Wei J, Nelson MD, et al. Cardiac magnetic resonance imaging for myocardial perfusion and diastolic function-reference control values for women. Cardiovasc Diagn Ther. 2016;6(1):78-86doi: 10.3978/j.issn.2223-3652.2015.09.03.
Bakir, M., Wei, J., Nelson, M. D., Mehta, P. K., Haftbaradaran, A., Jones, E., Gill, E., Sharif, B., Slomka, P. J., Li, D., Shufelt, C. L., Minissian, M., Berman, D. S., Bairey Merz, C. N., & Thomson, L. E. (2016). Cardiac magnetic resonance imaging for myocardial perfusion and diastolic function-reference control values for women. Cardiovascular diagnosis and therapy, 6(1), 78-86. https://doi.org/10.3978/j.issn.2223-3652.2015.09.03
Bakir, May, et al. "Cardiac magnetic resonance imaging for myocardial perfusion and diastolic function-reference control values for women." Cardiovascular diagnosis and therapy vol. 6,1 (2016): 78-86. doi: https://doi.org/10.3978/j.issn.2223-3652.2015.09.03
Bakir M, Wei J, Nelson MD, Mehta PK, Haftbaradaran A, Jones E, Gill E, Sharif B, Slomka PJ, Li D, Shufelt CL, Minissian M, Berman DS, Bairey Merz CN, Thomson LE. Cardiac magnetic resonance imaging for myocardial perfusion and diastolic function-reference control values for women. Cardiovasc Diagn Ther. 2016 Feb;6(1):78-86. doi: 10.3978/j.issn.2223-3652.2015.09.03. PMID: 26885495; PMCID: PMC4731584.
Copy Download .nbib Format: NLM
Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: From bench to bedside.

Expert review of ophthalmology

Rajaii F, McCoy AN, Smith TJ.
PMID: 25544859
Expert Rev Ophthalmol. 2014 Jun;9(3):227-234. doi: 10.1586/17469899.2014.917960.

The pathophysiology underlying Graves' disease and its ocular manifestation, thyroid associated ophthalmopathy (TAO) is incompletely understood. Characterization of the mononuclear cells driving the disease and the cytokines they produce has led to significant advances in our understanding of TAO....

Cite
Rajaii F, McCoy AN, Smith TJ. Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: From bench to bedside. Expert Rev Ophthalmol. 2014;9(3):227-234doi: 10.1586/17469899.2014.917960.
Rajaii, F., McCoy, A. N., & Smith, T. J. (2014). Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: From bench to bedside. Expert review of ophthalmology, 9(3), 227-234. https://doi.org/10.1586/17469899.2014.917960
Rajaii, Fatemeh, et al. "Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: From bench to bedside." Expert review of ophthalmology vol. 9,3 (2014): 227-234. doi: https://doi.org/10.1586/17469899.2014.917960
Rajaii F, McCoy AN, Smith TJ. Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: From bench to bedside. Expert Rev Ophthalmol. 2014 Jun;9(3):227-234. doi: 10.1586/17469899.2014.917960. PMID: 25544859; PMCID: PMC4275044.
Copy Download .nbib Format: NLM
Characterizing phenotype with tracer based metabolomics.

Metabolomics : Official journal of the Metabolomic Society

Lee WN.
PMID: 25540606
Metabolomics. 2006;2:31-39. doi: 10.1007/s11306-006-0017-3. Epub 2006 May 20.

In the post-genomic era, a pressing challenge to biological scientists is to understand the organization of gene functions, the interaction between gene and nutrient environment, and the genesis of phenotypes. Metabolomics, the quantitation of low molecular weight compounds, has...

Cite
Lee WN. Characterizing phenotype with tracer based metabolomics. Metabolomics. 2006;2:31-39doi: 10.1007/s11306-006-0017-3.
Lee, W. N. (2006). Characterizing phenotype with tracer based metabolomics. Metabolomics : Official journal of the Metabolomic Society, 231-39. https://doi.org/10.1007/s11306-006-0017-3
Lee, Wai Nang P. "Characterizing phenotype with tracer based metabolomics." Metabolomics : Official journal of the Metabolomic Society vol. 2 (2006): 31-39. doi: https://doi.org/10.1007/s11306-006-0017-3
Lee WN. Characterizing phenotype with tracer based metabolomics. Metabolomics. 2006;2:31-39. doi: 10.1007/s11306-006-0017-3. Epub 2006 May 20. PMID: 25540606; PMCID: PMC4271195.
Copy Download .nbib Format: NLM
Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle.

Metabolomics : Official journal of the Metabolomic Society

Zanuy M, Ramos-Montoya A, Villacañas O, Canela N, Miranda A, Aguilar E, Agell N, Bachs O, Rubio-Martinez J, Pujol MD, Lee WN, Marin S, Cascante M.
PMID: 22661920
Metabolomics. 2012 Jun 01;8(3):454-464. doi: 10.1007/s11306-011-0328-x. Epub 2011 Jul 08.

Cyclin-dependent kinases CDK4 and CDK6 are essential for the control of the cell cycle through the G(1) phase. Aberrant expression of CDK4 and CDK6 is a hallmark of cancer, which would suggest that CDK4 and CDK6 are attractive targets...

Cite
Zanuy M, Ramos-Montoya A, Villacañas O, et al. Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle. Metabolomics. 2011;8(3):454-464doi: 10.1007/s11306-011-0328-x.
Zanuy, M., Ramos-Montoya, A., Villacañas, O., Canela, N., Miranda, A., Aguilar, E., Agell, N., Bachs, O., Rubio-Martinez, J., Pujol, M. D., Lee, W. N., Marin, S., & Cascante, M. (2012). Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle. Metabolomics : Official journal of the Metabolomic Society, 8(3), 454-464. https://doi.org/10.1007/s11306-011-0328-x
Zanuy, Miriam, et al. "Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle." Metabolomics : Official journal of the Metabolomic Society vol. 8,3 (2012): 454-464. doi: https://doi.org/10.1007/s11306-011-0328-x
Zanuy M, Ramos-Montoya A, Villacañas O, Canela N, Miranda A, Aguilar E, Agell N, Bachs O, Rubio-Martinez J, Pujol MD, Lee WN, Marin S, Cascante M. Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle. Metabolomics. 2012 Jun 01;8(3):454-464. doi: 10.1007/s11306-011-0328-x. Epub 2011 Jul 08. PMID: 22661920; PMCID: PMC3361763.
Copy Download .nbib Format: NLM
Diverse mechanisms of growth inhibition by luteolin, resveratrol, and quercetin in MIA PaCa-2 cells: a comparative glucose tracer study with the fatty acid synthase inhibitor C75.

Metabolomics : Official journal of the Metabolomic Society

Harris DM, Li L, Chen M, Lagunero FT, Go VL, Boros LG.
PMID: 22754424
Metabolomics. 2012 Apr 01;8(2):201-210. doi: 10.1007/s11306-011-0300-9. Epub 2011 Mar 25.

The rationale of this dose matching/dose escalating study was to compare a panel of flavonoids-luteolin, resveratrol, and quercetin-against the metabolite flux-controlling properties of a synthetic targeted fatty acid synthase inhibitor drug C75 on multiple macromolecule synthesis pathways in pancreatic...

Cite
Harris DM, Li L, Chen M, et al. Diverse mechanisms of growth inhibition by luteolin, resveratrol, and quercetin in MIA PaCa-2 cells: a comparative glucose tracer study with the fatty acid synthase inhibitor C75. Metabolomics. 2011;8(2):201-210doi: 10.1007/s11306-011-0300-9.
Harris, D. M., Li, L., Chen, M., Lagunero, F. T., Go, V. L., & Boros, L. G. (2012). Diverse mechanisms of growth inhibition by luteolin, resveratrol, and quercetin in MIA PaCa-2 cells: a comparative glucose tracer study with the fatty acid synthase inhibitor C75. Metabolomics : Official journal of the Metabolomic Society, 8(2), 201-210. https://doi.org/10.1007/s11306-011-0300-9
Harris, Diane M, et al. "Diverse mechanisms of growth inhibition by luteolin, resveratrol, and quercetin in MIA PaCa-2 cells: a comparative glucose tracer study with the fatty acid synthase inhibitor C75." Metabolomics : Official journal of the Metabolomic Society vol. 8,2 (2012): 201-210. doi: https://doi.org/10.1007/s11306-011-0300-9
Harris DM, Li L, Chen M, Lagunero FT, Go VL, Boros LG. Diverse mechanisms of growth inhibition by luteolin, resveratrol, and quercetin in MIA PaCa-2 cells: a comparative glucose tracer study with the fatty acid synthase inhibitor C75. Metabolomics. 2012 Apr 01;8(2):201-210. doi: 10.1007/s11306-011-0300-9. Epub 2011 Mar 25. PMID: 22754424; PMCID: PMC3383678.
Copy Download .nbib Format: NLM
Treatment of angina and microvascular coronary dysfunction.

Current treatment options in cardiovascular medicine

Samim A, Nugent L, Mehta PK, Shufelt C, Bairey Merz CN.
PMID: 20842559
Curr Treat Options Cardiovasc Med. 2010 Aug;12(4):355-64. doi: 10.1007/s11936-010-0083-8.

OPINION STATEMENT: Microvascular coronary dysfunction (MCD) is an increasingly recognized cause of cardiac ischemia and angina that is diagnosed more commonly in women. Patients with MCD present with the triad of persistent chest pain, ischemic changes on stress testing,...

Cite
Samim A, Nugent L, Mehta PK, et al. Treatment of angina and microvascular coronary dysfunction. Curr Treat Options Cardiovasc Med. 2010;12(4):355-64doi: 10.1007/s11936-010-0083-8.
Samim, A., Nugent, L., Mehta, P. K., Shufelt, C., & Bairey Merz, C. N. (2010). Treatment of angina and microvascular coronary dysfunction. Current treatment options in cardiovascular medicine, 12(4), 355-64. https://doi.org/10.1007/s11936-010-0083-8
Samim, Arang, et al. "Treatment of angina and microvascular coronary dysfunction." Current treatment options in cardiovascular medicine vol. 12,4 (2010): 355-64. doi: https://doi.org/10.1007/s11936-010-0083-8
Samim A, Nugent L, Mehta PK, Shufelt C, Bairey Merz CN. Treatment of angina and microvascular coronary dysfunction. Curr Treat Options Cardiovasc Med. 2010 Aug;12(4):355-64. doi: 10.1007/s11936-010-0083-8. PMID: 20842559; PMCID: PMC3914311.
Copy Download .nbib Format: NLM
Religiosity and treatment response to antidepressant medication: A prospective multi-site clinical trial.

Mental health, religion & culture

Schettino JR, Olmos NT, Myers HF, Joseph NT, Poland RE, Lesser IM.
PMID: 22736954
Ment Health Relig Cult. 2011 Jan 01;14(8):805-818. doi: 10.1080/13674676.2010.527931. Epub 2011 Jun 13.

The present study examined the relationship between religiosity/spirituality and treatment response to antidepressant medication (citalopram). One-hundred and forty-eight Caucasian and African-American adults with uncomplicated major depression were treated with citalopram (20-60mg/day) over an 8-week period in a prospective multi-site...

Cite
Schettino JR, Olmos NT, Myers HF, et al. Religiosity and treatment response to antidepressant medication: A prospective multi-site clinical trial. Ment Health Relig Cult. 2011;14(8):805-818doi: 10.1080/13674676.2010.527931.
Schettino, J. R., Olmos, N. T., Myers, H. F., Joseph, N. T., Poland, R. E., & Lesser, I. M. (2011). Religiosity and treatment response to antidepressant medication: A prospective multi-site clinical trial. Mental health, religion & culture, 14(8), 805-818. https://doi.org/10.1080/13674676.2010.527931
Schettino, Jonathan R, et al. "Religiosity and treatment response to antidepressant medication: A prospective multi-site clinical trial." Mental health, religion & culture vol. 14,8 (2011): 805-818. doi: https://doi.org/10.1080/13674676.2010.527931
Schettino JR, Olmos NT, Myers HF, Joseph NT, Poland RE, Lesser IM. Religiosity and treatment response to antidepressant medication: A prospective multi-site clinical trial. Ment Health Relig Cult. 2011 Jan 01;14(8):805-818. doi: 10.1080/13674676.2010.527931. Epub 2011 Jun 13. PMID: 22736954; PMCID: PMC3380371.
Copy Download .nbib Format: NLM
Challenging Statin Pleiotropy: Preeclampsia.

Circulation

Wei J, Liao JK, Bairey Merz CN.
PMID: 34460319
Circulation. 2021 Aug 31;144(9):680-683. doi: 10.1161/CIRCULATIONAHA.121.056140. Epub 2021 Aug 30.

No abstract available.

Cite
Wei J, Liao JK, Bairey Merz CN. Challenging Statin Pleiotropy: Preeclampsia. Circulation. 2021;144(9):680-683doi: 10.1161/CIRCULATIONAHA.121.056140.
Wei, J., Liao, J. K., & Bairey Merz, C. N. (2021). Challenging Statin Pleiotropy: Preeclampsia. Circulation, 144(9), 680-683. https://doi.org/10.1161/CIRCULATIONAHA.121.056140
Wei, Janet, et al. "Challenging Statin Pleiotropy: Preeclampsia." Circulation vol. 144,9 (2021): 680-683. doi: https://doi.org/10.1161/CIRCULATIONAHA.121.056140
Wei J, Liao JK, Bairey Merz CN. Challenging Statin Pleiotropy: Preeclampsia. Circulation. 2021 Aug 31;144(9):680-683. doi: 10.1161/CIRCULATIONAHA.121.056140. Epub 2021 Aug 30. PMID: 34460319; PMCID: PMC8437106.
Copy Download .nbib Format: NLM
Strategies and methods to study female-specific cardiovascular health and disease: a guide for clinical scientists.

Biology of sex differences

Ouyang P, Wenger NK, Taylor D, Rich-Edwards JW, Steiner M, Shaw LJ, Berga SL, Miller VM, Merz NB.
PMID: 27034774
Biol Sex Differ. 2016 Mar 31;7:19. doi: 10.1186/s13293-016-0073-y. eCollection 2016.

BACKGROUND: In 2001, the Institute of Medicine's (IOM) report, "Exploring the Biological Contributions to Human Health: Does Sex Matter?" advocated for better understanding of the differences in human diseases between the sexes, with translation of these differences into clinical...

Cite
Ouyang P, Wenger NK, Taylor D, et al. Strategies and methods to study female-specific cardiovascular health and disease: a guide for clinical scientists. Biol Sex Differ. 2016;7:19doi: 10.1186/s13293-016-0073-y.
Ouyang, P., Wenger, N. K., Taylor, D., Rich-Edwards, J. W., Steiner, M., Shaw, L. J., Berga, S. L., Miller, V. M., & Merz, N. B. (2016). Strategies and methods to study female-specific cardiovascular health and disease: a guide for clinical scientists. Biology of sex differences, 719. https://doi.org/10.1186/s13293-016-0073-y
Ouyang, Pamela, et al. "Strategies and methods to study female-specific cardiovascular health and disease: a guide for clinical scientists." Biology of sex differences vol. 7 (2016): 19. doi: https://doi.org/10.1186/s13293-016-0073-y
Ouyang P, Wenger NK, Taylor D, Rich-Edwards JW, Steiner M, Shaw LJ, Berga SL, Miller VM, Merz NB. Strategies and methods to study female-specific cardiovascular health and disease: a guide for clinical scientists. Biol Sex Differ. 2016 Mar 31;7:19. doi: 10.1186/s13293-016-0073-y. eCollection 2016. PMID: 27034774; PMCID: PMC4815158.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 43 entries